EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis

Socorro Espuelas iD, Carmen Palomino-Cano iD, Carlos Torrado-Salmerón iD, Helga K Ruiz iD, Paloma M de la Torre-Iglesias iD, Santiago Torrado-Santiago iD, Juan J Torrado iD, José María Alunda iD, Christophe Dardonville iD, Sergio Alberto Sánchez Guirales iD, Dolores R Serrano iD, Javier Carrión iD

International Journal of Molecular Sciences · 10.07.2026 · 27 (14) · 6181

DOI: 10.3390/ijms27146181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.07.2026. Verfasst von Socorro Espuelas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Amphotericin B, Leishmaniasis, Cutaneous, Leishmania major, Antiprotozoal Agents. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Science and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous leishmaniosis (CL) remains a major neglected tropical disease, with current therapies constrained by toxicity, high cost, and variable efficacy. Here, we evaluated an immunochemotherapy strategy combining topical amphotericin B (AmB) with the therapeutic DNA vaccine HisAK70 in a murine model of Leishmania major infection. BALB/c mice were subcutaneously infected and treated with topical AmB cream alone, AmB plus HisAK70, or paromomycin (PM) as a reference therapy. Therapeutic efficacy was assessed through lesion progression, parasite burden in draining lymph nodes and spleen, and immunological markers associated with parasite control. Both PM and the combined AmB + HisAK70 treatment significantly reduced lesion progression and markedly decreased parasite burden compared with infected controls, demonstrating effective control of local infection and systemic dissemination. Importantly, the combination therapy enhanced the efficacy of AmB alone, supporting the beneficial contribution of vaccine-driven immune modulation to therapeutic outcome. Therapeutic efficacy was associated with reduced arginase activity in infected tissues and an increased IFN-γ/IL-4 ratio, indicative of a protective Th1-oriented immune response. Together, these findings highlight immunochemotherapy as a promising strategy for CL treatment, integrating localized topical drug delivery with targeted immune activation to improve therapeutic efficacy while potentially reducing systemic toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amphotericin BLeishmaniasis, CutaneousLeishmania majorAntiprotozoal AgentsVaccines, DNAImmunotherapyAnimalsMiceMice, Inbred BALB CFemaleInterleukin-4ParomomycinInterferon-gammaDisease Models, Animal

Stichwörter der Autor:innen

HisAK70Th1 immune responseamphotericin Bcutaneous leishmaniosisdrug repurposingimmunochemotherapyparomomycintherapeutic vaccinetopical therapy

Substanzen

Amphotericin BInterleukin-4Antiprotozoal AgentsVaccines, DNAParomomycinInterferon-gamma

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.
  • Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.
  • Instituto Universitario de Farmacia Industrial, Complutense University of Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
  • Group ICPVet, Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain.
  • Institute of Medicinal Chemistry (IQM-CSIC), 28006 Madrid, Spain.
  • Research Institute Hospital 12 de Octubre, 28041 Madrid, Spain.

ORCID-Profile: Socorro Espuelas, Carmen Palomino-Cano, Carlos Torrado-Salmerón, Helga K Ruiz, Paloma M de la Torre-Iglesias, Santiago Torrado-Santiago, Juan J Torrado, José María Alunda, Christophe Dardonville, Sergio Alberto Sánchez Guirales, Dolores R Serrano, Javier Carrión

Förderung

  • Spanish Ministry of Science and Innovation

Zitieren

APA

Espuelas, S., Palomino-Cano, C., Torrado-Salmerón, C., Ruiz, H. K., de la Torre-Iglesias, P. M., Torrado-Santiago, S., Torrado, J. J., Alunda, J. M., Dardonville, C., Sánchez Guirales, S. A., Serrano, D. R., & Carrión, J. (2026). Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis. International Journal of Molecular Sciences, 27(14), 6181. https://doi.org/10.3390/ijms27146181

Vancouver

Espuelas S, Palomino-Cano C, Torrado-Salmerón C, Ruiz HK, de la Torre-Iglesias PM, Torrado-Santiago S, et al. Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis. International Journal of Molecular Sciences. 2026;27(14):6181. doi:10.3390/ijms27146181

BibTeX
@article{Espuelas2026,
  author = {Espuelas, Socorro and Palomino-Cano, Carmen and Torrado-Salmerón, Carlos and Ruiz, Helga K and de la Torre-Iglesias, Paloma M and Torrado-Santiago, Santiago and Torrado, Juan J and Alunda, José María and Dardonville, Christophe and Sánchez Guirales, Sergio Alberto and Serrano, Dolores R and Carrión, Javier},
  title = {Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6181},
  doi = {10.3390/ijms27146181}
}
Kostenlos starten →